The review found no eligible studies for this question.
Summary of findings: Heparin showed no clear difference in mortality attributable to hepatic veno‐occlusive disease ( compared with no treatment (low certainty).
Summary of findings: Defibrotide showed no clear difference in mortality attributable to hepatic veno‐occlusive disease ( compared with no treatment (low certainty).
It is very uncertain whether summary of findings: Glutamine changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo (very low certainty).
It is very uncertain whether summary of findings: Ursodeoxycholic acid changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).
It is very uncertain whether summary of findings: Antithrombin III plus heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).
It is very uncertain whether summary of findings: Heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with low molecular weight heparin (very low certainty).
It is very uncertain whether summary of findings: Heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
It is very uncertain whether summary of findings: Low molecular weight heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
An extended NVP plus ZDV regimen administered to infants for 14 weeks showed no clear difference in infant Mortality at 24 months among those uninfected at birth compared with sdNVP plus ZDV (1 week) (moderate certainty).
An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in infant Mortality at 24 months among those uninfected at birth compared with an extended NVP regimen administered to infants (moderate certainty).
An extended NVP regimen administered to infants for 14 weeks showed no clear difference in infant Mortality at 24 months among those uninfected at birth compared with sdNVP plus ZDV (1week) (moderate certainty).
Parenteral nutrition plus branched‐chain‐amino‐acid‐enriched formula showed no clear difference in mortality [within first 10 weeks after liver transplantation] compared with standard isotonic intravenous glucose solution (low certainty).
Standard parenteral nutrition may leads to lower mortality [within first 10 weeks after liver transplantation] compared with standard isotonic intravenous glucose solution (low certainty).
Surgery showed no clear difference in disease-free survival (new disease, progression, and mortality) compared with radiotherapy alone (low certainty).
Sentinel node biopsy (neck dissection only if biopsy positive) showed no clear difference in disease-free survival (new disease, progression, and mortality) compared with elective neck dissection (low certainty).
Elective neck dissection (at time of primary tumour resection) probably leads to lower disease-free survival (new disease, progression, and mortality) compared with therapeutic (delayed) neck dissection (moderate certainty).
It is very uncertain whether elective radical (comprehensive) neck dissection changes disease-free survival (new disease, progression, and mortality) compared with elective selective neck dissection (very low certainty).